Phase I/II trial of SGI 1776 in patients with refractory leukaemias.

Trial Profile

Phase I/II trial of SGI 1776 in patients with refractory leukaemias.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2010

At a glance

  • Drugs SGI 1776 (Primary)
  • Indications Leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Nov 2010 Due to adverse events, the trial status changed from planning to discontinued, according to a SuperGen media release.
    • 04 Dec 2008 New trial record.
    • 20 Nov 2008 SuperGen has reported clearance of its Original Investigational New Drug Application in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top